Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tsoi, Man Fung ^a   Cheung, Ching Lung ^a,b   Cheung, Tommy Tsang ^a   Wong, Ian Chi Kei ^a,b   Kumana, Cyrus Rustam ^a   Tse, Hung Fat ^a   Cheung, Bernard Man Yung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); DRUG ELUTING STENT; FACTUAL DATABASE; HEMORRHAGE; HUMAN; META ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PROSTHESES AND ORTHOSES; RISK; THROMBOSIS;

ASPIRIN; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROSTHESES AND IMPLANTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK; THROMBOSIS;

EID: 84939600734     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13204     Document Type: Article

References (26)

1. Montalescot, G. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur. Heart J. 34, 2949-3003 (2013).
2. Hamm, C. W. et al ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32, 2999-3054 (2011).
3. Gwon, H. C. et al Six-month versus 12-month dual antiplatelet therapy afer implantation of drug-eluting stents: Te efcacy of xience/promus versus cypher to reduce late loss afer stenting (EXCELLENT) randomized, multicenter study. Circulation 125, 505-513 (2012).
4. Kim, B. K. et al A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efcacy of 3-month dual antiplatelet Terapy following Endeavor zotarolimus-eluting stent implantation). J. Am. Coll Cardiol. 60, 1340-1348 (2012).
5. Valgimigli, M. et al Short-versus long-term duration of dual-antiplatelet therapy afer coronary stenting: A randomized multicenter trial. Circulation 125, 2015-2026 (2012).
6. Feres, F. et al Tree vs twelve months of dual antiplatelet therapy afer zotarolimus-eluting stents: Te OPTIMIZE randomized trial. JAMA 310, 2510-2522 (2013).
7. Collet, J. P. et al Dual-antiplatelet treatment beyond 1 year afer drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384, 1577-1585 (2014).
8. Colombo, A. et al Second-Generation Drug-Eluting Stent Implantation Followed by 6-Versus 12-Month Dual Antiplatelet Terapy: Te SECURITY Randomized Clinical Trial. J. Am. Coll. Cardiol. 64, 2086-2097 (2014).
9. Gilard, M. et al Six-month versus 24-month dual antiplatelet therapy afer implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J. Am. Coll. Cardiol. 65, 777-786 (2015).
10. Lee C. W. et al Optimal Duration of Dual Antiplatelet Terapy Afer Drug-Eluting Stent Implantation A Randomized, Controlled Trial. Circulation 129, 304-312 (2014).
11. Mauri, L. et al Twelve or 30 Months of Dual Antiplatelet Terapy afer Drug-Eluting Stents. N. Engl. J. Med. doi: 10.1056/NEJMoa1409312 (2014).
12. Schulz-Schupke, S. et al ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy afer drug-eluting stenting. European heart journal doi: 10.1093/eurheartj/ehu523 (2015).
13. El-Hayek, G. et al Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am. J. Cardiol. 114, 236-242 (2014).
14. Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 137, 263-272 (2010).
15. Kumana, C. R., Cheung B. M. Y & Lauder I. J. Gauging the impact of statins using number needed to treat. JAMA 282, 1899-1901 (1999).
16. Pandit A., Giri, S., Hakim, F. A. & Fortuin, S. F. D. (/= 12 months) duration dual antiplatelet therapy afer drug eluting stents: A meta-analysis of randomized clinical trials. Catheter Cardio. Inte. doi: 10.1002/ccd.25520 (2014).
17. Elmariah, S. et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet doi: 10.1016/S0140-6736(14)62052-3 (2014).
18. Pisters, R. et al A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fbrillation: the Euro Heart Survey. Chest. 138, 1093-1100 (2010).
19. Palmerini, T. et al Mortality in patients treated with extended duration dual antiplatelet therapy afer drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet doi: 10.1016/s0140-6736(15)60263-x (2015).
20. Giustino, G. et al Duration of Dual Antiplatelet Terapy Afer Drug-Eluting Stent Implantation A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 65, 1298-1310 (2015).
21. Palmerini, T. et al Short-versus long-term dual antiplatelet therapy afer drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 65, 1092-1102 (2015).
22. Machado, C1. et al Second-generation versus frst-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease. Coron. Artery Dis. 24, 208-214 (2014).
23. Shimamura, K. et al Outcomes of everolimus-eluting stent incomplete stent apposition: a serial optical coherence tomography analysis. Eur. Heart. J. Cardiovasc. Imaging doi: 10.1093/ehjci/jeu174 (2014).
24. Kaiser, C. et al Long-Term Efcacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents: Main Results of the Basel Stent Kosten-Efektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), A Randomized, Controlled Noninferiority 2-Year Outcome Trial. Circulation doi: 10.1161/CIRCULATIONAHA.114.013520 (2014).
25. Mehran, R. et al Standardized bleeding defnitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123, 2736-2747 (2011).
26. Tygesen, K., Alpert, J. S. & Jafe, A. S. et al Tird universal defnition of myocardial infarction. Circulation 126, 2020-2035 (2012).